Ignite Creation Date:
2024-05-05 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00483535
Status:
TERMINATED
Last Update Posted:
2017-08-08
First Post:
2007-06-06
Brief Title:
Oral Contraceptive Interaction Study for GW273225
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
An Open Repeat Dose Study to Investigate the Effect of Co-administration of the Combined Oral Contraceptive Pill COC and GW273225 on the Pharmacokinetics of the COC and to Investigate the Effects of the COC on the Pharmacokinetics of GW273225 in Healthy Female Subjects
Status:
TERMINATED
Status Verified Date:
2017-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
GW273225 is in development for epilepsy and bipolar disorder and can affect women of child bearing potential A clear understanding of the potential interaction between oral contraceptives and GW273225 is therefore important for clinical investigation of GW273225 in a large number of patients This study will investigate whether there is any effect of GW273225 upon the components of combined oral contraceptive and also whether taking oral contraceptives affects the pharmacokinetics PK of GW273225
26 healthy female subjects aged 18-45 years will take an oral contraceptive 150ug levonorgestrel and 30ug ethinylestrdiol The study will include a screening period two cycles on oral contraceptive with GW273225 at 25 mg once per day administered from the start of the second COC cycle for 47 days There will be a follow-up visit 14-21 days later
26 healthy female subjects aged 18-45 years will take an oral contraceptive 150ug levonorgestrel and 30ug ethinylestrdiol The study will include a screening period two cycles on oral contraceptive with GW273225 at 25 mg once per day administered from the start of the second COC cycle for 47 days There will be a follow-up visit 14-21 days later
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None